Selected article for: "International license and medical care"
Author: Malahat Khalili; Mohammad Karamouzian; Naser Nasiri; Sara Javadi; Ali Mirzazadeh; Hamid Sharifi
Title: Epidemiological Characteristics of COVID-19: A Systemic Review and Meta-Analysis
  • Document date: 2020_4_6
    • ID: e3t1f0rt_23
    Snippet: In compare to MERS-COV with a mortality rate of 35.67% (34) and SARS with a mortality rate 264 of 11% (35), we found that COVID-19 has a much lower mortality rate (2%) which significantly 265 increase by age (48% increase for every 1% increase in male participants). Although this 266 estimate is comparable with previous studies (36, 37), it is important to recognize the 267 limitations of calculating mortality rates of COVID-19 while the epidemic.....
    Document: In compare to MERS-COV with a mortality rate of 35.67% (34) and SARS with a mortality rate 264 of 11% (35), we found that COVID-19 has a much lower mortality rate (2%) which significantly 265 increase by age (48% increase for every 1% increase in male participants). Although this 266 estimate is comparable with previous studies (36, 37), it is important to recognize the 267 limitations of calculating mortality rates of COVID-19 while the epidemic is still growing. As 268 most cases of CVOID-19 remain asymptomatic and may recover without seeking medical care, 269 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • asymptomatic remain and International license: 1, 2, 3
    • asymptomatic remain and mortality rate: 1, 2, 3, 4
    • asymptomatic remain and previous study: 1
    • cc NC ND International license and epidemic grow: 1
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and male participant: 1, 2, 3, 4, 5
    • cc NC ND International license and medical care: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cc NC ND International license and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • cc NC ND International license and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • epidemic grow and International license: 1
    • International license and low mortality rate: 1, 2
    • International license and male participant: 1, 2, 3, 4, 5
    • International license and medical care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • International license and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • International license and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • low mortality rate and medical care: 1, 2, 3
    • low mortality rate and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • low mortality rate and previous study: 1
    • medical care and previous study: 1, 2, 3, 4, 5, 6, 7, 8